Trial Profile
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Astrocytoma; Glioma
- Focus Therapeutic Use
- Acronyms PNOC 001
- 19 Jul 2023 Planned End Date changed from 30 Apr 2024 to 31 Jul 2024.
- 29 Jan 2021 Planned End Date changed from 31 Jan 2028 to 30 Apr 2024.
- 25 Mar 2020 Planned End Date changed from 30 Nov 2022 to 31 Jan 2028.